MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - indian pharma
- CIPLA - ASTRAZENECA PHARMA
CIPLA vs ASTRAZENECA PHARMA - Comparison Results
CIPLA Change
Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More
ASTRAZENECA PHARMA 
AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More
Current Valuations
| CIPLA | ASTRAZENECA PHARMA | CIPLA/ ASTRAZENECA PHARMA |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 22.6 | 94.2 | 24.0% | View Chart |
| P/BV | x | 2.5 | 26.5 | 9.4% | View Chart |
| Dividend Yield | % | 0.6 | 0.0 | - |
Financials
 CIPLA  ASTRAZENECA PHARMA |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| CIPLA Mar-19 |
ASTRAZENECA PHARMA Mar-18 |
CIPLA/ ASTRAZENECA PHARMA |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 678 | 1,278 | 53.1% | |
| Low | Rs | 484 | 883 | 54.8% | |
| Sales per share (Unadj.) | Rs | 198.2 | 228.4 | 86.8% | |
| Earnings per share (Unadj.) | Rs | 18.5 | 10.4 | 178.7% | |
| Cash flow per share (Unadj.) | Rs | 35.0 | 16.3 | 215.2% | |
| Dividends per share (Unadj.) | Rs | 3.00 | 0 | - | |
| Dividend yield (eoy) | % | 0.5 | 0 | - | |
| Book value per share (Unadj.) | Rs | 186.3 | 98.8 | 188.6% | |
| Shares outstanding (eoy) | m | 805.70 | 25.00 | 3,222.8% | |
| Bonus/Rights/Conversions | ESOP | - | - | ||
| Price / Sales ratio | x | 2.9 | 4.7 | 62.0% | |
| Avg P/E ratio | x | 31.4 | 104.2 | 30.1% | |
| P/CF ratio (eoy) | x | 16.6 | 66.4 | 25.0% | |
| Price / Book Value ratio | x | 3.1 | 10.9 | 28.5% | |
| Dividend payout | % | 16.2 | 0 | - | |
| Avg Mkt Cap | Rs m | 468,031 | 27,008 | 1,733.0% | |
| No. of employees | `000 | 22.6 | 1.4 | 1,669.9% | |
| Total wages/salary | Rs m | 28,565 | 1,535 | 1,860.6% | |
| Avg. sales/employee | Rs Th | 7,053.1 | 4,210.9 | 167.5% | |
| Avg. wages/employee | Rs Th | 1,261.5 | 1,132.2 | 111.4% | |
| Avg. net profit/employee | Rs Th | 659.1 | 191.1 | 344.9% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 159,710 | 5,710 | 2,797.0% | |
| Other income | Rs m | 4,766 | 123 | 3,890.4% | |
| Total revenues | Rs m | 164,475 | 5,833 | 2,820.0% | |
| Gross profit | Rs m | 30,973 | 463 | 6,691.1% | |
| Depreciation | Rs m | 13,263 | 147 | 8,998.0% | |
| Interest | Rs m | 1,684 | 0 | - | |
| Profit before tax | Rs m | 20,791 | 438 | 4,746.9% | |
| Minority Interest | Rs m | -172 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 5,695 | 179 | 3,183.5% | |
| Profit after tax | Rs m | 14,924 | 259 | 5,760.1% | |
| Gross profit margin | % | 19.4 | 8.1 | 239.2% | |
| Effective tax rate | % | 27.4 | 40.8 | 67.1% | |
| Net profit margin | % | 9.3 | 4.5 | 205.9% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 124,266 | 3,209 | 3,872.2% | |
| Current liabilities | Rs m | 37,715 | 2,070 | 1,822.4% | |
| Net working cap to sales | % | 54.2 | 20.0 | 271.5% | |
| Current ratio | x | 3.3 | 1.6 | 212.5% | |
| Inventory Days | Days | 91 | 72 | 125.3% | |
| Debtors Days | Days | 95 | 35 | 271.6% | |
| Net fixed assets | Rs m | 105,190 | 790 | 13,310.2% | |
| Share capital | Rs m | 1,611 | 50 | 3,222.8% | |
| "Free" reserves | Rs m | 148,511 | 2,419 | 6,138.6% | |
| Net worth | Rs m | 150,123 | 2,469 | 6,079.6% | |
| Long term debt | Rs m | 38,301 | 0 | - | |
| Total assets | Rs m | 239,633 | 4,605 | 5,203.3% | |
| Interest coverage | x | 13.3 | NM | - | |
| Debt to equity ratio | x | 0.3 | 0 | - | |
| Sales to assets ratio | x | 0.7 | 1.2 | 53.8% | |
| Return on assets | % | 6.9 | 5.6 | 123.2% | |
| Return on equity | % | 9.9 | 10.5 | 94.7% | |
| Return on capital | % | 11.8 | 17.7 | 66.7% | |
| Exports to sales | % | 34.7 | 0 | - | |
| Imports to sales | % | 0 | 0 | - | |
| Exports (fob) | Rs m | 55,419 | NA | - | |
| Imports (cif) | Rs m | NA | NA | - | |
| Fx inflow | Rs m | 57,410 | 300 | 19,165.2% | |
| Fx outflow | Rs m | 19,041 | 2,015 | 945.0% | |
| Net fx | Rs m | 38,368 | -1,715 | -2,236.7% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 16,911 | 88 | 19,239.4% | |
| From Investments | Rs m | -16,687 | -94 | 17,827.8% | |
| From Financial Activity | Rs m | -3,487 | NA | - | |
| Net Cashflow | Rs m | -3,451 | -6 | 60,545.6% | |
Share Holding
| Indian Promoters | % | 16.0 | 0.0 | - | |
| Foreign collaborators | % | 20.8 | 75.0 | 27.7% | |
| Indian inst/Mut Fund | % | 12.2 | 0.3 | 4,066.7% | |
| FIIs | % | 23.7 | 15.7 | 151.0% | |
| ADR/GDR | % | 1.1 | 0.0 | - | |
| Free float | % | 26.2 | 9.1 | 287.9% | |
| Shareholders | 161,166 | 12,856 | 1,253.6% | ||
| Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare CIPLA With: TTK HEALTHCARE ALEMBIC LTD DR. REDDYS LAB ELDER PHARMA UNICHEM LAB
Compare CIPLA With: MYLAN (US) ADCOCK INGRAM (S. Africa) ACTAVIS (US) TEVA PHARMA (Israel)
|
| |
Today's Market
Sensex Ends 70 Points Higher; Telecom and Banking Stocks Advance(Closing)
Indian share markets traded on a positive note throughout the day and ended marginally higher. The BSE Sensex rose over 350 points intraday.
Related Views on News
CIPLA Announces Quarterly Results (2QFY20); Net Profit Up 31.2% (Quarterly Result Update)
Nov 14, 2019 | Updated on Nov 14, 2019For the quarter ended September 2019, CIPLA has posted a net profit of Rs 5 bn (up 31.2% YoY). Sales on the other hand came in at Rs 44 bn (up 9.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.
CIPLA 2018-19 Annual Report Analysis (Annual Result Update)
Sep 9, 2019 | Updated on Sep 9, 2019Here's an analysis of the annual report of CIPLA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.
CIPLA Announces Quarterly Results (1QFY20); Net Profit Up 5.6% (Quarterly Result Update)
Aug 13, 2019 | Updated on Aug 13, 2019For the quarter ended June 2019, CIPLA has posted a net profit of Rs 5 bn (up 5.6% YoY). Sales on the other hand came in at Rs 40 bn (up 1.3% YoY). Read on for a complete analysis of CIPLA's quarterly results.
ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)
Aug 8, 2019 | Updated on Aug 8, 2019For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)
May 27, 2019 | Updated on May 27, 2019For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
More Views on NewsMost Popular
Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)
Nov 7, 2019Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?
Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)
Nov 8, 2019Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.
These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)
Nov 5, 2019How to avoid the most common investing mistake and make the most of the smallcap rebound.
The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)
Nov 5, 2019Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.
What to Buy at Sensex 40,000(The 5 Minute Wrapup)
Nov 4, 2019Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?
MoreCIPLA SHARE PRICE
Nov 15, 2019 (Close)
TRACK CIPLA
- Track your investment in CIPLA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON CIPLA
CIPLA - TORRENT PHARMA COMPARISON
COMPARE CIPLA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.